AstraZeneca Pharmaceuticals LP
NEWS
Eli Lilly and Company published results from a new Phase IIIb clinical trial of Trulicity (dulaglutide) in combination with a sodium-glucose co-transporter-2 (SGLT-2) inhibitor, which has shown improved blood sugar control in adults with type 2 diabetes.
The U.S. Food and Drug Administration (FDA) approved AstraZeneca’s Imfinzi to treat patients with unresectable Stage III non-small cell lung cancer (NSCLC).
AstraZeneca did not immediately respond to a request for comment.
Failing numbers are putting a strain on CEO Pascal Soriot’s pledge of achieving $45B of annual revenue by 2023.
Despite some safety concerns such as severe diarrhea, the FDA approved Puma’s breast cancer drug Nerlynx in July 2017.
The survey of 51 oncologists suggests broad uptake of Imfinzi in advanced lung cancer patients who can’t be treated with surgery.
Astra has seen a fourfold increase in research productivity following a narrowing of disease focus and cuts in laboratory and staff over the past seven years, Reuters reported Thursday.
The company’s vaccine controversy could cause legal and image problems for years to come.
JOBS
IN THE PRESS